Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schweiger, M; Stiegler, P; Puntschart, A; Sereinigg, M; Prenner, G; Wasler, A; Tscheliessnigg, K.
Everolimus in different combinations as maintenance immunosuppressive therapy in heart transplant recipients.
Exp Clin Transplant. 2012; 10(3):273-277
Doi: 10.6002/ect.2011.0156
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Schweiger Martin
- Co-Autor*innen der Med Uni Graz
- Grün Andreas Jürgen
- Prenner Günther
- Sereinigg Michael
- Stiegler Philipp
- Tscheliessnigg Karlheinz
- Wasler Andrae
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Objectives: We examined the experiences of heart transplant recipients receiving everolimus as maintenance therapy in different combinations over a long time. Materials and Methods: Between 2004 and 2009, forty patients (29 men, 11 women; mean age, 51.6 y) were switched from a routine immunosuppressive regimen to everolimus. Indications were other (2), renal insufficiency (17), cardiac allograft vasculopathy (14), and ongoing cellular rejection (7). Combinations were either along with cyclosporine (24), mycophenolate mofetil (14), or others (2). Indications for the introduction of everolimus including safety, efficacy, different combinations of everolimus, biopsy-proven acute rejections, renal function, and infections were evaluated retrospectively. Results: Five patients died, 4 of them were still on everolimus at the time of death; they died from intracerebral hemorrhage (1), embolism (1), cardiac arrest (2), and unknown (1). Everolimus was discontinued in 6 patients owing to severe adverse effects: Edema (2), gastrointestinal adverse effects (3), and dermal adverse effects (1). Mean everolimus trough levels were 5.8 mu mol/L at 6 months and 4.9 at 60 months. Mean cyclosporine levels were 67.62 mu mol/L at 6 months and 47.3 mu mol/L at 60 months. Mean serum creatinine levels were stable (147.9 mu mol/L after 60 months). Four life-threatening infections (all pneumonia) occurred but resulted in complete recovery. Conclusions: Everolimus is safe with different immunosuppressive combinations after receiving a heart transplant.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Biopsy -
- Cyclosporine - therapeutic use
- Drug Therapy, Combination -
- Edema - chemically induced
- Female -
- Gastrointestinal Diseases - chemically induced
- Graft Rejection - immunology
- Heart Transplantation - immunology
- Humans -
- Immunosuppressive Agents - therapeutic use
- Incidence -
- Longitudinal Studies -
- Male -
- Middle Aged -
- Mycophenolic Acid - analogs & derivatives
- Retrospective Studies -
- Sirolimus - adverse effects
- Treatment Outcome -
- Find related publications in this database (Keywords)
- Renal failure
- Proliferation inhibitors
- Calcineurin inhibitor-free protocols
- Midterm follow-up